5VA Stock Overview
A clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vaxcyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$100.00 |
| 52 Week High | US$100.00 |
| 52 Week Low | US$62.00 |
| Beta | 0.99 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 140.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5VA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.2% | -1.9% |
| 1Y | n/a | -9.6% | 12.3% |
Return vs Industry: Insufficient data to determine how 5VA performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 5VA performed against the German Market.
Price Volatility
| 5VA volatility | |
|---|---|
| 5VA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5VA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 5VA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 254 | Grant Pickering | vaxcyte.com |
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Vaxcyte, Inc. Fundamentals Summary
| 5VA fundamental statistics | |
|---|---|
| Market cap | €12.54b |
| Earnings (TTM) | -€452.99m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-27.7x
P/E RatioIs 5VA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5VA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$75.00m |
| Gross Profit | -US$75.00m |
| Other Expenses | US$422.19m |
| Earnings | -US$497.19m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.02 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 5VA perform over the long term?
See historical performance and comparison